Loading...
Loading...
TCRR| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 29.2M |
| Operating I/L | -29.2M |
| Other Income/Expense | 0.1M |
| Interest Income | 0.1M |
| Pretax | -29.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -29.1M |
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company specializing in developing T cell receptor (TCR) therapies for cancer patients. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, currently in phase I/II clinical trial for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Additionally, TCR2 Therapeutics Inc. is developing TC-510, a mesothelin-targeted TRuC-T cell for solid tumor treatment, and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for renal cell carcinoma treatment.
